At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 107 enrolled
Drug / intervention
AKST4290 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating AKST4290, Placebo, and 1 other intervention for Neovascular Age-related Macular Degeneration. Completed, enrolled 107 participants across 21 sites in 4 countries.
Detailed Summary
This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, Hungary, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
First PostedApr 2020
Primary CompletionAug 2021
Study CompletionSep 2021
TodayJul 2026
First PostedApr 2, 2020
Enrollment StartJan 28, 2020
Primary CompletionAug 19, 2021
Study CompletionSep 16, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.3 years ago
Interventions
AKST4290drug
Oral AKST4290
Placebodrug
Oral placebo
Afliberceptdrug
Aflibercept intravitreal injection